Aveo Pharmaceuticals (AVEO) Share Value Declined While Venbio Select Advisor Decreased Its Holding by $5.48 Million; Boeing Co (BA) Stock Value Rose While Hirtle Callaghan & Co Lifted Position

January 19, 2018 - By Migdalia James

Venbio Select Advisor Llc decreased its stake in Aveo Pharmaceuticals Inc (AVEO) by 27.53% based on its latest 2017Q3 regulatory filing with the SEC. Venbio Select Advisor Llc sold 1.83M shares as the company’s stock declined 7.05% while stock markets rallied. The institutional investor held 4.81M shares of the health care company at the end of 2017Q3, valued at $17.54M, down from 6.63M at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Aveo Pharmaceuticals Inc for a number of months, seems to be less bullish one the $435.47M market cap company. The stock increased 2.35% or $0.07 during the last trading session, reaching $2.84. About 561,719 shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 16.67% since January 19, 2017 and is downtrending. It has underperformed by 33.37% the S&P500.

Hirtle Callaghan & Co Llc increased its stake in Boeing Co (BA) by 4402.17% based on its latest 2017Q3 regulatory filing with the SEC. Hirtle Callaghan & Co Llc bought 8,100 shares as the company’s stock rose 4.66% with the market. The institutional investor held 8,284 shares of the aerospace company at the end of 2017Q3, valued at $2.11 million, up from 184 at the end of the previous reported quarter. Hirtle Callaghan & Co Llc who had been investing in Boeing Co for a number of months, seems to be bullish on the $200.64B market cap company. The stock decreased 0.96% or $3.28 during the last trading session, reaching $336.88. About 4.90M shares traded or 31.00% up from the average. The Boeing Company (NYSE:BA) has risen 41.13% since January 19, 2017 and is uptrending. It has outperformed by 24.43% the S&P500.

Investors sentiment decreased to 0.81 in 2017 Q3. Its down 0.05, from 0.86 in 2017Q2. It is negative, as 50 investors sold BA shares while 609 reduced holdings. 165 funds opened positions while 367 raised stakes. 411.79 million shares or 1.95% less from 419.99 million shares in 2017Q2 were reported. Coastline Trust Co has 2,930 shares. Loring Wolcott & Coolidge Fiduciary Advisors Llp Ma holds 0.04% of its portfolio in The Boeing Company (NYSE:BA) for 8,889 shares. Guardian Limited Partnership accumulated 7,530 shares. Independence holds 5.31% or 18,315 shares in its portfolio. Jump Trading Limited Liability Co, a Illinois-based fund reported 563 shares. Capital One Natl Association stated it has 18,253 shares. Cannell Peter B holds 0.06% of its portfolio in The Boeing Company (NYSE:BA) for 6,790 shares. Segantii Capital Management Limited stated it has 0.5% of its portfolio in The Boeing Company (NYSE:BA). Moreover, Hbk Sorce Advisory Lc has 0.26% invested in The Boeing Company (NYSE:BA). Tdam Usa Inc, a Ontario – Canada-based fund reported 128,009 shares. Richard Bernstein Advsr Limited Liability reported 24,957 shares. 149,185 are owned by Teachers Retirement Sys Of The State Of Kentucky. Advisor Ptnrs Ltd Limited Liability Company invested in 11,500 shares or 0.57% of the stock. Nine Masts Capital holds 0.16% or 4,264 shares. Round Table Ltd Company holds 0.1% or 1,101 shares.

Since July 31, 2017, it had 0 insider buys, and 5 insider sales for $20.35 million activity. Another trade for 4,217 shares valued at $1.02M was sold by CAPOZZI HEIDI B. 134 The Boeing Company (NYSE:BA) shares with value of $32,321 were sold by Downey Thomas J. Muilenburg Dennis A sold $13.84M worth of The Boeing Company (NYSE:BA) on Monday, July 31. Shares for $616,499 were sold by Verbeck Robert E on Monday, July 31.

Among 23 analysts covering Boeing (NYSE:BA), 15 have Buy rating, 1 Sell and 7 Hold. Therefore 65% are positive. Boeing had 91 analyst reports since August 26, 2015 according to SRatingsIntel. The company was maintained on Wednesday, June 21 by Cowen & Co. The rating was maintained by Canaccord Genuity on Wednesday, July 26 with “Hold”. The rating was maintained by RBC Capital Markets on Friday, October 6 with “Hold”. The firm has “Sell” rating by Standpoint Research given on Wednesday, October 26. Barclays Capital maintained the shares of BA in report on Thursday, October 6 with “Overweight” rating. The rating was upgraded by Credit Suisse to “Outperform” on Thursday, July 27. The firm has “Sell” rating by RBC Capital Markets given on Friday, June 2. The stock has “Overweight” rating by JP Morgan on Friday, July 14. On Thursday, July 27 the stock rating was upgraded by RBC Capital Markets to “Sector Perform”. Robert W. Baird initiated it with “Outperform” rating and $161 target in Thursday, October 6 report.

Hirtle Callaghan & Co Llc, which manages about $24.08 billion and $1.01B US Long portfolio, decreased its stake in Ishares Msci Emerging Mkts (EEM) by 18,870 shares to 2.71M shares, valued at $121.55M in 2017Q3, according to the filing.

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals had 11 analyst reports since March 30, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 9 by Piper Jaffray. The firm has “Buy” rating by FBR Capital given on Monday, June 26. As per Wednesday, March 30, the company rating was initiated by FBR Capital. Piper Jaffray initiated the shares of AVEO in report on Thursday, May 19 with “Overweight” rating. FBR Capital maintained the shares of AVEO in report on Thursday, December 7 with “Buy” rating. Piper Jaffray upgraded AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rating on Monday, August 28. Piper Jaffray has “Buy” rating and $4.5 target. The firm earned “Buy” rating on Tuesday, January 16 by FBR Capital. As per Thursday, October 5, the company rating was maintained by Piper Jaffray.

Analysts await AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report earnings on March, 28. They expect $-0.03 EPS, up 72.73% or $0.08 from last year’s $-0.11 per share. After $-0.02 actual EPS reported by AVEO Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.

Venbio Select Advisor Llc, which manages about $380.08 million and $1.29 billion US Long portfolio, upped its stake in Medicines Co (NASDAQ:MDCO) by 1.52 million shares to 1.72 million shares, valued at $63.72 million in 2017Q3, according to the filing. It also increased its holding in Assembly Biosciences Inc (NASDAQ:ASMB) by 300,000 shares in the quarter, for a total of 907,162 shares, and has risen its stake in Biomarin Pharmaceutical Inc (NASDAQ:BMRN).

Investors sentiment increased to 1.32 in Q3 2017. Its up 0.23, from 1.09 in 2017Q2. It is positive, as 10 investors sold AVEO shares while 12 reduced holdings. 14 funds opened positions while 15 raised stakes. 59.90 million shares or 5.78% less from 63.58 million shares in 2017Q2 were reported. Fincl Bank Of America De accumulated 6,000 shares. Gemmer Asset Management Ltd stated it has 0.01% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). State Street Corp reported 92,375 shares. Venbio Select Advisor Ltd Liability Corp invested in 1.36% or 4.81M shares. Nea Ltd Liability Co invested 2.09% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Edge Wealth Limited Liability Corporation holds 0.01% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 10,000 shares. Jane Street Gru Ltd Company, New York-based fund reported 14,007 shares. Excalibur Corporation holds 0.03% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 11,000 shares. California Public Employees Retirement holds 33,400 shares. Deer Vi And Ltd Com, a New York-based fund reported 675,242 shares. Spark Inv Limited Com has invested 0.08% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Barclays Plc has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Ra Capital Mngmt Ltd Liability Corporation invested in 11.33 million shares or 3.74% of the stock. Northern Corp holds 0% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 206,033 shares. Perceptive Advsr Ltd owns 3.42 million shares or 0.48% of their US portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts